Rhenman & Partners Asset Management AB Buys Shares of 8,000 United Therapeutics Corporation $UTHR

Rhenman & Partners Asset Management AB purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 8,000 shares of the biotechnology company’s stock, valued at approximately $3,354,000.

Other hedge funds have also made changes to their positions in the company. Clearstead Advisors LLC raised its position in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Bessemer Group Inc. increased its stake in United Therapeutics by 2.6% in the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock valued at $472,000 after purchasing an additional 28 shares during the last quarter. Archer Investment Corp raised its holdings in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 31 shares in the last quarter. F m Investments LLC lifted its position in shares of United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after buying an additional 33 shares during the last quarter. Finally, WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the sale, the chief financial officer owned 8,142 shares in the company, valued at $3,896,761.20. The trade was a 72.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 377,184 shares of company stock worth $183,015,947 in the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $478.16 on Friday. The firm has a market cap of $20.96 billion, a price-to-earnings ratio of 17.14, a price-to-earnings-growth ratio of 1.72 and a beta of 0.84. The firm’s fifty day moving average price is $482.51 and its 200 day moving average price is $453.25. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $537.19.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.19 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on UTHR. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. TD Cowen lifted their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. UBS Group lifted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, HC Wainwright increased their price objective on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.